Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.42 |
| ▸ | ACP3 | P15309 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | ALPI | P09923 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | XIAP | P98170 | 1/20 | 0.37 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10701392 | 0.81 | SLC6A2 (0.40) | EPHX1ACP3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8556445 | 0.80 | PRSS1 (0.52) | — | |
| SCHEMBL27372 | 0.78 | LMNA (0.42) | SLC6A4CYP1A2PKMSLC7A5ALDH1A1 | |
| SCHEMBL11480147 | 0.78 | GSR (0.37) | SLC6A4CYP1A2PKMSMN1; SMN2TAAR1 | |
| SCHEMBL11852683 | 0.78 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3ALDH1A1HTT | |
| SCHEMBL971331 | 0.77 | SLC6A2 (0.47) | EPHX1ACP3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3678018 | 0.76 | TAAR1 (0.48) | EPHX1SLC6A2SLC6A4SLC6A3CYP1A2 | |
| SCHEMBL734453 | 0.76 | PBRM1 (0.41) | SLC6A2SLC6A4CYP1A2PKMALDH1A1 | |
| SCHEMBL1432767 | 0.76 | AOC3 (0.39) | SLC6A2SLC6A4SLC6A3CHRM1CYP1A2 | |
| SCHEMBL9067637 | 0.74 | EPHX1 (0.52) | EPHX1ACP3CHRM1CYP1A2SRR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103768073-B | There is the application in preparation antiviral drugs of the steroid derivative of double hydrazone structure | 湖北省生物农药工程研究中心 | 2017-01-04 | — | — | CN | claimed |
| US-8969546-B2 | Compounds useful in imaging and therapy | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2015-03-03 | — | — | US | claimed |
| US-20130211066-A1 | COMPOUNDS USEFUL IN IMAGING AND THERAPY | ALBERTA HEALTH SERVICES (CA) | 2013-08-15 | — | — | US | claimed |
| US-11926633-B2 | Synthesis methods for upadacitinib and intermediate thereof | SUZHOU PENGXU PHARMATECH CO., LTD (CN) | 2024-03-12 | — | — | US | disclosed |
| US-20210323971-A1 | SYNTHESIS METHODS FOR UPADACITINIB AND INTERMEDIATE THEREOF | SUZHOU PENGXU PHARMATECH CO., LTD (CN) | 2021-10-21 | — | — | US | disclosed |
| CN-105001226-B | Tricyclic heterocyclic compounds and JAK inhibitor | 日产化学工业株式会社 | 2017-09-08 | — | — | CN | disclosed |
| CN-103732597-B | Tricyclic heterocyclic compounds and JAK inhibitors | 日产化学工业株式会社 | 2016-08-17 | — | — | CN | disclosed |
| CN-105001226-A | Tricycle heterocyclic compounds and JAK inhibitors | NISSAN CHEMICAL IND LTD | 2015-10-28 | — | — | CN | disclosed |
| US-8969546-B2 | Compounds useful in imaging and therapy | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2015-03-03 | — | — | US | disclosed |
| CN-103732597-A | Tricyclic heterocyclic compounds and JAK inhibitors | NISSAN CHEMICAL IND LTD | 2014-04-16 | — | — | CN | disclosed |
| US-20130211066-A1 | COMPOUNDS USEFUL IN IMAGING AND THERAPY | ALBERTA HEALTH SERVICES (CA) | 2013-08-15 | — | — | US | disclosed |
| EP-1751087-B1 | LEVODOPA DERIVATIVES, AND COMPOSITIONS AND USES THEREOF | XENOPORT INC (US) | 2012-06-27 | — | — | EP | disclosed |
| WO-2011160216-A2 | COMPOUNDS USEFUL IN IMAGING AND THERAPY | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2011-12-29 | — | — | WO | disclosed |
| WO-2008093960-A1 | NOVEL DIPEPTIDYL PEPTIDASE-IV INHIBITORS | LG LIFE SCIENCES, LTD. (KR) | 2008-08-07 | — | — | WO | disclosed |
| EP-1131290-B1 | PIPERIDINE CCR-3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-02-20 | — | — | EP | disclosed |
| US-6342509-B1 | ANTIASTHMATICS, ANTIHISTAMINES OR BRONCHODIALATORS | SYNTEX (U.S.A.) LLC | 2002-01-29 | — | — | US | disclosed |
| EP-1131290-A1 | PIPERIDINE CCR-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-09-12 | — | — | EP | disclosed |
| WO-2000031033-A1 | PIPERIDINE CCR-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323971-A1 | SYNTHESIS METHODS FOR UPADACITINIB AND INTERMEDIATE THEREOF | JAK1, JAK3, JAK2 | EPHX1 2345/4885ACP3 2229/4885SLC6A2 4683/4885 |
| US-11926633-B2 | Synthesis methods for upadacitinib and intermediate thereof | JAK1, JAK3, JAK2 | EPHX1 2345/4885ACP3 2229/4885SLC6A2 4683/4885 |
| US-20130211066-A1 | COMPOUNDS USEFUL IN IMAGING AND THERAPY | PAICS, MPI, ALDOA | EPHX1 4709/4885ACP3 3695/4885SLC6A2 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.